|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Alveolar and bronchial epithelial cells have been shown to have regulatory functions in the maintenance of lung structure and function. Recent evidence supports the premise that these cells can synthesize a variety of extracellular matrix components in vitro, suggesting an active participation in connective tissue remodeling. Their possible role in extracellular matrix degradation, however, is less clear. This study addresses the question of whether alveolar and bronchial epithelial cells express the highly collagenolytic and elastinolytic cysteine proteinase cathepsin K, which has recently been newly described. We provide evidence that the epithelial cell lines A549 and BEAS-2B are capable of expressing cathepsin K messenger RNA. Furthermore, we show that cathepsin K is expressed in normal bronchial epithelial cells. Western blot analyses of human lung-tissue lysates revealed specific immunoreactivity at molecular weights of 46 and 27 kD, corresponding to the procathepsin and the mature cathepsin K. Immunohistochemical analyses showed a pronounced staining of bronchial epithelial cells and in single alveolar epithelial cells. Using a specific fluorogenic cytochemical assay, the intracellular activity of the enzyme was localized. These findings demonstrate that bronchial and alveolar epithelial cells are capable of expressing cathepsin K, which could be of considerable importance for remodeling processes of the extracellular matrix in the lung.
| |
Introduction |
|---|
|
|
|---|
Bronchial and alveolar epithelial cells play an important role in the maintenance of lung structure and function. Goblet cells, Clara cells, and alveolar type II epithelial cells are major producers of components of the pulmonary secretions such as mucin and surfactant. In addition, pulmonary epithelial cells can synthesize a variety of extracellular matrix components and therefore participate in basement membrane and connective tissue metabolism (1, 2). However, little information exists about their possible role in the destructive pathway of components of the interstitial matrix.
Cysteine proteinases (such as cathepsins B, L, S, and H) are thought to be the major proteinases involved in intracellular protein degradation (3). Several studies have shown the release of enzymatically active cathepsins from bronchial epithelial cells (4) and the involvement of these proteases in tissue degeneration (7) and tumor progression (8).
A novel human cysteine protease was recently cloned by several groups (9) and named cathepsin K. It shows a high-sequence homology to the cathepsins S and L. This protease was shown to be expressed predominantly in osteoclasts (12). Recent data have demonstrated that pycnodysostosis is caused by mutations in the cathepsin K gene (15, 16). The expression of cathepsin K in the lung and in other tissues is controversial. Brömme and Okamoto (12) showed a significant messenger RNA (mRNA) expression in the lung tissue, whereas Drake and coworkers (13) described an exclusive expression in bone.
Cathepsin K seems to be the cysteine protease with the highest matrix degradation activity yet known. It was shown that cathepsin K cleaves collagen type I with higher efficiency than do cathepsin L and S. Its elastinolytic activity is higher than that of cathepsin L and pancreatic elastase (17). The capability of cathepsin K to degrade components of the extracellular matrix, especially of elastin at neutral pH, suggests an involvement of this protease in the process of tissue destruction and remodeling in the lung. Fundamental data on the occurrence and the activity of this particular enzyme are missing as yet.
Using a combination of immunologic, enzymologic, and molecular biologic methods, this study demonstrates that cathepsin K is expressed in the lung tissue and shows the cellular distribution of this enzyme.
| |
Materials and Methods |
|---|
|
|
|---|
Lung-tissue samples were obtained at surgery from patients with lung tumors. The samples were isolated from areas without morphologic signs of neoplastic cells. The tissue was formalin-fixed and paraffin-embedded for use in immunhistologic studies, or shock-frozen in liquid nitrogen. The alveolar epithelial cell-like tumor cell line A549 was obtained from DSMZ (Braunschweig, Germany). The cell line BEAS-2B, which was derived from virus-transformed human bronchial epithelial cells, was a kind gift from A. Gillissen (Klinikum Bergmannsheil, Bochum, Germany). Both cell lines were grown in Iscove's modified Dulbecco's medium with 10% fetal calf serum (both from PAA Laboratories, Cölbe, Germany), 1% antibiotic-antimycotic solution (Sigma, Deissenhofen, Germany) and 1 mM N-2-hydroxyethylpiperazine-N'-ethane sulfonic acid (Life Technologies, Eggenstein, Germany).
The polyclonal anti-cathepsin K antiserum was raised in rabbits against recombinant cathepsin K as described previously (10). Recombinant cathepsin K was purified from the culture supernatant of Pichia pastoris transfected with human procathepsin K complementary DNA (cDNA) (18). For reverse transcriptase-polymerase chain reaction (RT-PCR) experiments, sense and antisense primers were designed using previously published cDNA sequences for the human cathepsins K, B, and L (12, 19). Specific sense and antisense primers were selected as follows: cathepsin K: sense primer 5'-TCCATCCATAACCTTGAGGCTT, antisense primer 5'-CCACAGCCATCATTCTCAGACACA; cathepsin B: sense primer 5'-GCCTGCAAGCTTCGATGCAC, antisense primer 5'-CTATTGGAGACGCTGTAGGA; cathepsin L: sense primer 5'-CAGGCAGGTGATGAATGGCT, antisense primer 5'-CAGGCCTCCATTATCCTGAA. These primers corresponded to cDNA fragments of 361, 464, and 324 base pair (bp) bases for the cathepsins K, B, and L, respectively. The primers were synthesized and purified by Life Technologies.
For Northern blot analyses of cathepsin K, the resulting PCR products were 32P-labeled, using the Rediprime labeling kit (Amersham, Braunschweig, Germany).
The substrates benzyloxycarbonyl-phenyl-arginyl-7-amido-4-methylcoumarin (Z-FR-AMC), benzyloxycarbonyl-glycyl-prolyl-arginyl - 7 - amido - 4 - methylcoumarin
(Z-GPR-AMC), benzyloxycarbonyl-glycyl-prolyl-arginyl-4-methoxy-
-naphtylamine (Z-GPR-4M
NA), and benzyloxycarbonyl-arginyl-arginyl - 4 - methoxy -
- naphtylamine
(Z-RR-4M
NA) were obtained from Bachem (Heidelberg, Germany). The cysteine protease inhibitors L-trans-epoxysuccinyl-Leu-4-guanidinobutylamide (E64) and L-trans-epoxysuccinyl-Ile-Pro-OH propylamide (CA074) were obtained from Sigma and Bachem, respectively.
Northern Blot Analysis
PolyA mRNA was prepared with Dynabeads (Dynal,
Oslo, Norway) according to the manufacturer's instructions. mRNA (2 µg) from the epithelial cell lines A549
and BEAS-2B was electrophoresed on a formalin gel
(1.2%) and the RNA was blotted onto a nylon membrane.
Cathepsin K mRNA was detected by a radioactively labeled cDNA probe (310 bp) for 4 h at 65°C in Rapid Hyb
Buffer (Amersham). The blots were washed twice and exposed to Kodak BioMax MS-1 film at
70°C for 14 h. Following hybridization with cathepsin K, blots were stripped
and rehybridized with
-actin as a semiquantitative control. These blots were exposed for 4 h.
PCR Analysis
Total RNA was isolated using the RNeasy kit (Qiagene, Hilden, Germany). The RT reaction and the PCR amplification were done exactly as described by Alcorn and associates (20) using the thermocycler PTC-200 (MJ Research, Inc., Watertown, MA) and touchdown cycling protocol. The amplified products were verified by their predicted sizes. In addition, random samples were digested with appropriate restriction enzymes (SalI, Sau3aI, and BglII). All products were visualized after electrophoresis on an ethidium bromide-stained 2% agarose gel (MetaPhor agarose; FMC, Rockland ME).
Flow Cytometric Analysis
Cells were permeabilized using the Fix & Perm Kit (An der Grub, Kaumberg, Austria) and incubated with the cathepsin K antiserum (diluted 1:10) for 60 min. The samples were washed and incubated with fluorescein isothiocyanate (FITC)-conjugated rabbit antiserum (DIANOVA, Hamburg, Germany) for 60 min. For specificity control experiments, cathepsin K antiserum was preincubated with saturating amounts of purified cathepsin K for 60 min and used for intracellular staining as indicated. The samples were analyzed by means of flow cytometry (FACSCalibur; Becton Dickinson, Heidelberg, Germany).
Western Blot Analysis
Frozen samples of lung tissue were crushed in liquid nitrogen before addition of lysis buffer (50 mM Tris, 0.75% Triton X-100, 10 mg/ml phenylmethylsulfonyl fluoride, 1 mg/ml Aprotinin, and 1 mg/ml Leupeptin. The tissue samples were incubated for 20 min on ice, reducing sample buffer was added, and the probes were boiled for 5 min before being loaded onto a 15% sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) gel. After separation, the proteins were transferred to an enhanced chemiluminescence (ECL)-nitrocellulose membrane (Amersham). Nonspecific binding was blocked by overnight incubation in sodium phosphate buffer (PBS) containing 5% nonfat dried milk. The transfers were then incubated for 90 min with cathepsin K antiserum (1:5,000 in PBS/Tween). The blots were washed and incubated for 90 min with peroxidase-labeled antirabbit F(ab)2 (1:5,000), and visualized using the chemiluminescent SuperSignal substrate (Pierce, Rockford, IL). For detection of cystatin B expression, the blots were stained with a rabbit anti-cystatin B-antibody (1:1,000; Quartett, Berlin, Germany). The blots were developed using the ProtoBlot Western Blot AP System (Promega, Madison, WI).
Immunohistochemistry
Paraffin-embedded tissue blocks were cut, using a microtome, and the 5-µm sections were placed on coated glass slides. The sections were dried overnight, dewaxed in xylene, and rehydrated into 0.1 M Tris buffer. After three washing steps in Tris buffer, the sections were overlaid either with the rabbit cathepsin K antiserum (1:2,000) or with antiserum preincubated with saturating amounts of purified cathepsin K (negative control). A standard avidin-biotin complex method (alkaline phosphatase) was performed according to the manufacturer's protocol (Vectastain Kit; Boehringer Ingelheim, Heidelberg, Germany). New fuchsin was used a substrate. Sections were counterstained with hematoxylin and mounted in gelatin.
Enzymatic Activity of Cell Lysates
Pellets of the cell lines A549 and BEAS-2B were lysed in assay buffer (50 mM sodium acetate buffer, pH 5.5, containing 2.5 mM dithiothreitol [DTT] and 2.5 mM ethylenediaminetetraacetic acid [EDTA]) with 1% Triton X-100. The samples were centrifuged at 14,000 × g for 10 min, and the resulting supernatants were used for determination of enzymatic activity as described by Kirschke and Wiederanders (21), with minor modifications. Briefly, supernatants of 5 × 105 cells were incubated with one of the methylcoumarylamide substrates, Z-FR-AMC (5 µM) or Z-GPR-AMC (80 µM), for 1,000 s, and the reaction was terminated by the addition of stop buffer (3). The resulting fluorescence was measured using a Fluorolite microplate reader (Dynex, Chantilly, VA).
Cytochemical Cathepsin K Activity
Cathepsin K activity was detected at the cellular level according to the method of Dolbeare and Smith (22) by
means of the substrate Z-GPR-4M
NA (1 mg/ml) and the
cathepsin B-specific inhibitor CA074 (10 µM). In control
experiments, the cathepsin B activity was visualized with
the substrate Z-RR-4M
NA (1 mM). The liberated 4M
NA
was precipitated and detected by 5-nitro-salicylaldehyde (Sigma). The reaction buffer was 0.1 M PBS, pH 6.0, supplemented with 1.3 mM EDTA, 1 mM DTT, and 3 mM
L-cysteine. The cells were harvested from cultures and
seeded on glass slips. After an incubation period of 24 h,
the cells were fixed in 1% formaldehyde for 10 min at
room temperature, washed in the reaction buffer, and incubated with the substrate solution at 37°C for 20 min. The
reaction was stopped by several washes with PBS. The
slips were mounted on glass slides. The fluorescence was
monitored with an Axiovert microscope (Zeiss, Jena, Germany) equipped with a BP 450-490/FT 510/LP 515-565.
| |
Results |
|---|
|
|
|---|
The cathepsin K expression was characterized at mRNA, protein, and enzymatic levels using different molecular biologic, immunochemical, and biochemical methods.
Expression of Cathepsin K mRNA
The DNA transcription is the first prerequisite of protein expression. The mRNA synthesis is strongly regulated for the majority of proteins. To characterize the expression of the cathepsin K mRNA, lung epithelial cell lines and lung tissues were analyzed using PCR and Northern blotting.
Northern blot analyses of the mRNA isolated from the
epithelial cell lines BEAS-2B and A549 with a specific
probe for cathepsin K demonstrated a single band of 1.7 kb (Figure 1). For estimation of the relative amounts of
the cathepsin K mRNA expression in comparison with the
cathepsins B and L, RT-PCR analyses of the cell lines
were performed. As documented in Figure 2A, the level of
the cathepsin K expression was significantly lower than
those of the cathepsins B and L in BEAS-2B cells and
lower than that of cathepsin L in A549 cells. Figure 2B
shows the mRNA expression of the cathepsins B, L, and K
in lung tissues of two patients. The PCR shown in the figures was performed from the same RNA preparation for
the three cathepsins and
-actin. One representative experiment is shown, out of the three runs of each PCR for
each cathepsin and
-actin.
|
|
Cathepsin K Protein Expression
The cathepsin K protein expression in lysates of cell lines and lung tissues was studied by flow cytometry, immunohistochemistry, and Western blotting.
In the lung epithelial cell lines A549 and BEAS-2B, a method for cytoplasmic immunostaining of cathepsin K and their flow cytometric detection was established. The presence of the cathepsin K protein could be demonstrated in both cell types (Figure 3). In Western blots of the cell lines A549 and BEAS-2B, significant amounts of cystatin B could be visualized (Figure 4).
|
|
In lysates of normal human lung tissue, the cathepsin K antiserum hybridized with major immunoreactive bands at molecular weights of 46, 27, and 12 kD (Figure 5). These bands correspond to the expected molecular weights of procathepsin K (46 kD) and mature cathepsin K (27 kD) (10, 14). It could be assumed that the 12-kD band corresponds to the propeptide.
|
Using a specific cathepsin K antiserum, immunoreactivity was tested in paraffin-embedded lung tissues of six patients. Distinct immunoreactions were abundant in ciliated and nonciliated bronchial epithelial cells (Figures 6A and 6C). The specificity of the immunoreaction was shown in control experiments in which the antiserum was preincubated with purified cathepsin K; no staining was detectable in these slides (Figure 6B).
|
Specific Enzymatic Activity
For determination of the resulting enzymatic cathepsin K activities, lysates of the cell lines BEAS-2B and A459 were incubated with Z-GPR-AMC, which was shown to be specific for cathepsin K (23). The Michaelis constant (Km) value for this substrate, determined using standard procedures, was 44 µM. The substrate Z-GPR-AMC was found not to be cleaved by the cathepsins L and S (data not shown). Cathepsin B cleaved this substrate at rates at least 50-fold lower than the cleaving rates for cathepsin K. Parallel samples of the cell lysates were incubated with Z-FR-AMC. To characterize further the enzymatic activity, the cell lysates were incubated with both Z-GPR-AMC and Z-FR-AMC in the presence of the inhibitors E64, a cysteine protease inhibitor, and CA074, which was specific for cathepsin B (data not shown). As documented in Figure 7, the cleavage of Z-GPR-AMC and Z-FR-AMC was strongly inhibited by E64 and CA074. These results show that the enzymatic activity measured in the cell lysates results exclusively from a cathepsin B-like cysteine protease.
|
The intracellular activity of cathepsin K was further
verified by enzyme cytochemistry. The cathepsin K-reactive sites in the A549 and the BEAS-2B (data not shown)
cells were visualized with the substrate Z-GPR-4M
NA
and the inhibitor CA074. Interestingly, a significant perinuclear enzymatic activity was shown (Figure 8A). This
activity persisted after incubation in the presence of the inhibitor CA074 (Figure 8B). However, the cleavage of the cathepsin B-specific substrate Z-RR-4M
NA (Figure 8C)
was strongly suppressed by the same inhibitor (Figure
8D). These results suggest that the substrate Z-GPR-4M
NA is cleaved by cathepsin K intracellularly.
|
| |
Discussion |
|---|
|
|
|---|
Cathepsin K is a recently identified member of the papain family of cysteine proteinases that appears to play an important role in matrix degradation (12, 24). This enzyme shows strong proteolytic activity at acidic pH and, in comparison with the cathepsins B and L, significant activity at neutral pH (10, 23). It has been demonstrated to degrade elastin and type I collagen as well as denatured type I collagen. Northern blot analyses have documented that cathepsin K is abundantly expressed in osteoclasts (9, 13, 14). Cathepsin K mRNA expression was also shown in lung tissues (9, 12), in monocyte-derived macrophages (13, 19) and in subpopulations of mononuclear marrow cells and breast carcinoma cells (13, 14, 25).
Collagen and elastin fibers form a network around the alveoli and the bronchial ducts, exerting tension in the alveolar and bronchial walls to counter the outward tension. Whereas elastin synthesized in childhood ordinarily lasts a lifetime (26), the collagen synthesis and degradation is regulated more rapidly (27). Many lung diseases are characterized by a modified extracellular matrix metabolism. Destruction of connective tissue is a crucial process in the mechanism of adult respiratory distress syndrome and other acute inflammatory diseases of the lung. The damage to the extracellular matrix is immediately followed by an upregulation of collagen de novo synthesis and the repair of elastin fibers (28). Lack of tight regulation of these processes may lead to fibrosis of the lung with potential irreversible dysfunction. A number of studies showed the role of elastase, released from infiltrating neutrophil granulocytes, in the inflammation-dependent tissue destruction. It was shown that matrix-metalloproteinases released from alveolar macrophages and epithelial cells may also play an important role in the pathogenesis of several lung diseases (31). Less information exists about the role of cysteine proteinases released from bronchial and alveolar epithelial cells.
Considering the first data concerning the expression in the lung and the unusual high collagenolytic and elastinolytic activity of the newly described cathepsin K, our aim was to study the expression and the proteolytic activity of this cysteine protease, particularly in lung epithelial cells.
Here we have presented evidence that human bronchial and alveolar epithelial cells express both the mRNA and the protein of cathepsin K. Initially we studied the mRNA expression of transformed lung epithelial cells. The cell line A549 is an epithelial lung tumor cell line with features of alveolar type II epithelial cells (35). The cell line BEAS-2B was established by viral transformation of human bronchial epithelial cells (36). In Northern blot analyses we detected the expression of a single 1.7-kb mRNA transcript in both cell lines. RT-PCR studies of the relative mRNA levels in lung tissues and cell lines suggested that the cathepsin K mRNA is expressed at somewhat lower levels than the mRNAs of cathepsins B and L. Although the PCRs were performed from the same RNA preparation, only a semiquantitative evaluation of the number of mRNA transcripts was possible because of methodologic limitations. The results correlate well to the results published by Brömme and Okamoto showing a borderline cathepsin K mRNA expression in A549 cells (12). These data clearly show that, in contrast to the osteoclastic cells, the cathepsin K mRNA is not dominant in lung epithelial cells. To investigate the relevance of our findings in nontransformed lung tissues, we studied the cathepsin K mRNA expression in human lung tissues with the help of PCR analyses. These experiments revealed, like the findings in the cell lines, a lower level of mRNA for cathepsin K than for the cathepsins B and L.
The protein expression of cathepsin K was demonstrated by means of flow cytometry. Using the specific cathepsin K antiserum, we documented the intracellular localization of this protein. This methodical approach may be helpful in future studies concerning the regulation of cathepsin expression.
The Western blot analyses of lung-tissue lysates showed a specific expression of three major immunoreactive bands that correspond to the pro- and the mature forms of the protease. Different molecular weights of the proenzyme between 37 and 46 kD are shown by several groups. In giant cell tumors beside a dominant 39-kD procathepsin, Littlewood-Evans and colleagues showed a distinct staining for cathepsin K at 46 kD (14). The variation in the molecular weights of the proenzyme published by different groups could result from different molecular forms of the protease, as shown for cathepsin B (37), or from methodologic limitations in definition of the molecular weights using SDS-PAGE. It could be suggested that the 12-kD band was the cleaved propeptide. The staining of a protein at 20 kD was inconsistent in tissue lysates from different patients. Further experiments must be performed to characterize the 12- and 20-kD proteins.
Immunohistochemical analyses of paraffin-embedded lung tissues revealed a specific staining of bronchial epithelial cells as well as single alveolar epithelial cells. The immunoreactivity of the antibody could be blocked by preincubation with purified cathepsin K. The results were verified using two different antisera raised against recombinant cathepsin K from P. pastoris (18) and a synthetic peptide corresponding to the cathepsin K sequence as described by Drake and associates (13). Especially within the bronchial epithelial cells, part of the immunoreactivity was localized in the apical part of the cells near the cell membrane. Burnett and coworkers have shown a secretion of procathepsin B by bronchial epithelial cells (4). Pardo and coworkers (33) studied the secretion of gelatinases by alveolar epithelial cells. Their zymographic figures clearly show a gelatinolytic activity at molecular weights below 50 kD, indicating a distinct enzymatic activity in addition to the activity of gelatinase A at molecular weights higher than 50 kD (33). These data, together with the described gelatinolytic activity of cathepsin K, suggest a possible secretion of the enzyme into the extracellular space.
In other studies concerning the cathepsin K expression in human embryonal lung tissues, the expression pattern in bronchial epithelial cells was confirmed by in situ hybridization (C. Häckel, manuscript submitted).
We extended our study to investigate whether these epithelial cells exhibit a significant enzymatic cathepsin K activity. Aibe and coworkers showed that the substrate Z-GPR-AMC is cleaved exclusively by cathepsin K (23). Our own studies, revealing a Km of 44 µM for cathepsin K, no cleavage by the cathepsins S and L, and more than 50-fold lower cleavage rates for cathepsin B, supported these findings. The substrate Z-GPR-AMC was shown to be specific for cathepsin K, and Z-FR-AMC was cleaved by cathepsins L, B, and K (3). The inhibitor CA074 selectively suppressed the enzymatic activity of cathepsin B but not the activity of cathepsins K and L. The inhibitor E64 suppressed the activity of cathepsins B, L, and K. Using a combination of these substrates and inhibitors it was possible to measure the enzymatic activity of cathepsins K, B, and L in parallel. Our data show that in lysates of the epithelial cell lines, only the enzymatic activity of cathepsin B was detectable. The activities of cathepsins K and L could not be detected. Previous studies (38) showed significantly lower inhibition constant (Ki) values for the inhibition of cathepsin L by the cystatins A and B in comparison with cathepsin B. Our measurements show Ki values at subnanomolar levels for cathepsin K (D. Brömme, unpublished). As documented in Figure 4, bronchial epithelial cells do express cystatin B. Therefore, the data suggest that in cell lysates the activity of cathepsin K as well as cathepsin L could be inhibited by these cystatins. On the other hand, cytochemical detection revealed a significant specific activity of cathepsin K localized in cellular compartments without specific inhibitors, which was not inhibited by CA074 (Figure 8). Further studies will clarify the functional significance of cathepsin K in the epithelial collagenolytic and elastinolytic activity mediated by cysteine proteases.
In summary, our results demonstrate that bronchial and alveolar epithelial cells do express cathepsin K. These data are consistent with the observation that these cells actively participated in the extracellular matrix turnover. The functional significance in physiologic and pathologic processes in the lung as well as the regulation of the expression of cathepsin K remain to be investigated.
| |
Footnotes |
|---|
Address correspondence to: Frank Bühling, Institute of Immunology, Otto von Guericke University Magdeburg, Leipziger-Str. 44, 39120 Magdeburg, Germany. E-mail: frank.buehling{at}medizin.uni-magdeburg.de
(Received in original form April 29, 1998 and in revised form August 26, 1998).
Abbreviations: cysteine protease inhibitor L-trans-epoxysuccinyl-Ile-Pro-OH propylamide, CA074; complementary DNA, cDNA; dithiothreitol, DTT; cysteine protease inhibitor L-trans-epoxysuccinyl-Leu-4-guanidinobutylamide, E64; ethylenediaminetetraacetic acid, EDTA; messenger RNA, mRNA; sodium phosphate buffer, PBS; reverse transcriptase-polymerase chain reaction, RT-PCR; sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SDS-PAGE; benzyloxycarbonyl-phenyl-arginyl-7-amido-4-methylcoumarin substrate, Z-FR-AMC; benzyloxycarbonyl-glycyl-prolyl-arginyl-4-methoxy-
-naphtylamine substrate, Z-GPR-4M
NA;
benzyloxycarbonyl-glycyl-prolyl-arginyl-7-amido-4-methylcoumarin substrate, Z-GPR-AMC; benzyloxycarbonyl-arginyl-arginyl-4-methoxy-
-naphtylamine substrate, Z-RR-4M
NA.
Acknowledgments: The authors thank Ms. Marianne Blichmann and Ms. Gabriele Weitz for their technical assistance. This work was supported by the Deutsche Forschungsgemeinschaft, SFB 387/B-7.
| |
References |
|---|
|
|
|---|
1.
Guadiz, G.,
L. A. Sporn, and
P. J. Simpson-Haidaris.
1997.
Thrombin cleavage-independent deposition of fibrinogen in extracellular matrices.
Blood
90:
2644-2653
2.
Guadiz, G.,
L. A. Sporn,
R. A. Goss,
S. O. Lawrence,
V. J. Marder, and
P. J. Simpson-Haidaris.
1997.
Polarized secretion of fibrinogen by
lung epithelial cells.
Am. J. Respir. Cell Mol. Biol.
17:
60-69
3. Barrett, A. J., and H. Kirschke. 1981. Cathepsin B, cathepsin H, and cathepsin L. Methods Enzymol. 80: 535-561 .
4. Burnett, D., M. Abrahamson, J. L. Devalia, R. J. Sapsford, R. J. Davies, and D. J. Buttle. 1995. Synthesis and secretion of procathepsin B and cystatin C by human bronchial epithelial cells in vitro: modulation of cathepsin B activity by neutrophil elastase. Arch. Biochem. Biophys. 317: 305-310 [Medline].
5. Buttle, D. J., M. Abrahamson, D. Burnett, J. S. Mort, A. J. Barrett, P. M. Dando, and S. L. Hill. 1991. Human sputum cathepsin B degrades proteoglycan, is inhibited by alpha 2-macroglobulin and is modulated by neutrophil elastase cleavage of cathepsin B precursor and cystatin C. Biochem. J. 276: 325-331 .
6. Buttle, D. J., B. C. Bonner, D. Burnett, and A. J. Barrett. 1988. A catalytically active high-Mr form of human cathepsin B from sputum. Biochem. J. 254: 693-699 [Medline].
7.
Reddy, V. Y.,
Q. Y. Zhang, and
S. J. Weiss.
1995.
Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and
S, by human monocyte-derived macrophages.
Proc. Natl. Acad. Sci.
USA
92:
3849-3853
8. Werle, B., B. Jülke, T. Lah, E. Spiess, and W. Ebert. 1997. Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung. Br. J. Cancer 75: 1137-1143 [Medline].
9. Inaoka, T., G. Bilbe, O. Ishibashi, K. Tezuka, M. Kumegawa, and T. Kokubo. 1995. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun. 206: 89-96 [Medline].
10.
Bromme, D.,
K. Okamoto,
B. B. Wang, and
S. Biroc.
1996.
Human
cathepsin O2, a matrix protein-degrading cysteine protease expressed
in osteoclasts: functional expression of human cathepsin O2 in Spodoptera
frugiperda and characterization of the enzyme.
J. Biol. Chem.
271:
2126-2132
11.
Shi, G. P.,
J. S. Munger,
J. P. Meara,
D. H. Rich, and
H. A. Chapman.
1992.
Molecular cloning and expression of human alveolar macrophage cathepsin
S, an elastinolytic cysteine protease.
J. Biol. Chem.
267:
7258-7262
12. Bromme, D., and K. Okamoto. 1995. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol. Chem. Hoppe Seyler 376: 379-384 [Medline].
13.
Drake, F. H.,
R. A. Dodds,
I. E. James,
J. R. Connor,
C. Debouck,
S. Richardson,
E. Lee-Rykaczewski,
L. Coleman,
D. Rieman,
R. Barthlow,
G. Hastings, and
M. Gowen.
1996.
Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.
J. Biol.
Chem.
271:
12511-12516
14. Littlewood-Evans, A., T. Kokubo, O. Ishibashi, T. Inaoka, B. Wlodarski, J. A. Gallagher, and G. Bilbe. 1997. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry. Bone 20: 81-86 [Medline].
15. Gelb, B. D., G. P. Shi, H. A. Chapman, and R. J. Desnick. 1996. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273: 1236-1238 [Abstract].
16.
Johnson, M. R.,
M. H. Polymeropoulos,
H. L. Vos,
R. I. O. De Luna, and
C. A. Francomano.
1996.
A nonsense mutation in the cathepsin K
gene observed in a family with pycnodysostosis.
Genome Res.
6:
1050-1055
17. Chapman, H. A., R. J. Riese, and G. P. Shi. 1997. Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol. 59: 63-88 [Medline].
18. Linnevers, C. J., M. E. McGrath, R. Armstrong, F. R. Mistry, M. G. Barnes, J. L. Klaus, J. T. Palmer, B. A. Katz, and D. Brömme. 1997. Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex. Protein Sci. 6: 919-921 [Abstract].
19. Shi, G. P., H. A. Chapman, S. M. Bhairi, C. DeLeeuw, V. Y. Reddy, and S. J. Weiss. 1995. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett. 357: 129-134 [Medline].
20.
Alcorn, J. L.,
M. E. Smith,
J. F. Smith,
L. R. Margraf, and
C. R. Mendelson.
1997.
Primary cell culture of human type II pneumonocytes: maintenance
of a differentiated phenotype and transfection with recombinant adenoviruses.
Am. J. Respir. Cell Mol. Biol.
17:
672-682
21. Kirschke, H., and B. Wiederanders. 1994. Cathepsin S and related lysosomal endopeptidases. Methods Enzymol. 244: 500-511 [Medline].
22.
Dolbeare, A. F., and
E. R. Smith.
1977.
Flow cytometric measurement of
peptidases with use of 5-nitrosalicylaldehyde and 4-methoxy-beta-naphthylamine derivatives.
Clin. Chem.
23:
1485-1491
23. Aibe, K., H. Yazawa, K. Abe, K. Teramura, M. Kumegawa, H. Kawashima, and K. Honda. 1996. Substrate specificity of recombinant osteoclast-specific cathepsin K from rabbits. Biol. Pharm. Bull. 19: 1026-1031 [Medline].
24.
Bossard, M. J.,
T. A. Tomaszek,
S. K. Thompson,
B. Y. Amegadzie,
C. R. Hanning,
C. Jones,
J. T. Kurdyla,
D. E. McNulty,
F. H. Drake,
M. Gowen, and
M. A. Levy.
1996.
Proteolytic activity of human osteoclast cathepsin
K: expression, purification, activation, and substrate identification.
J. Biol.
Chem.
271:
12517-12524
25.
Littlewood-Evans, A. J.,
G. Bilbe,
W. B. Bowler,
D. Farley,
B. Wlodarski,
T. Kokubo,
T. Inaoka,
J. Sloane,
D. B. Evans, and
J. A. Gallagher.
1997.
The osteoclast-associated protease cathepsin K is expressed in human
breast carcinoma.
Cancer Res.
57:
5386-5390
26.
Kuhn, C..
1997.
Repairing the cables of the lung.
Am. J. Respir. Cell Mol.
Biol.
17:
287-288
27. Finlay, G. A., M. D. O'Donnell, C. M. O'Connor, J. P. Hayes, and M. X. Fitzgerald. 1996. Elastin and collagen remodeling in emphysema: a scanning electron microscopy study. Am. J. Pathol. 149: 1405-1415 [Abstract].
28.
Deheinzelin, D.,
F. B. Jatene,
P. H. Saldiva, and
R. R. Brentani.
1997.
Upregulation of collagen messenger RNA expression occurs immediately after lung damage.
Chest
112:
1184-1188
29. Bienkowski, R. S., and M. G. Gotkin. 1995. Control of collagen deposition in mammalian lung. Proc. Soc. Exp. Biol. Med. 209: 118-140 [Abstract].
30. Karsenty, G., and R. W. Park. 1995. Regulation of type I collagen genes expression. Int. Rev. Immunol. 12: 177-185 [Medline].
31.
Finlay, G. A.,
L. R. O'Driscoll,
K. J. Russell,
E. M. D'Arcy,
J. B. Masterson,
M. X. Fitzgerald, and
C. M. O'Connor.
1997.
Matrix metalloproteinase expression and production by alveolar macrophages in emphysema.
Am. J. Respir. Crit. Care Med.
156:
240-247
32. Torii, K., K. I. Iida, Y. Miyazaki, S. Saga, Y. Kondoh, H. Taniguchi, F. Taki, K. Takagi, M. Matsuyama, and R. Suzuki. 1997. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 155: 43-46 [Abstract].
33. Pardo, A., K. Ridge, B. Uhal, J. I. Sznajder, and M. Selman. 1997. Lung alveolar epithelial cells synthesize interstitial collagenase and gelatinases A and B in vitro. Int. J. Biochem. Cell Biol. 29: 901-910 [Medline].
34.
Yao, P. M.,
B. Maitre,
C. Delacourt,
J. M. Buhler,
A. Harf, and
C. Lafuma.
1997.
Divergent regulation of 92-kDa gelatinase and TIMP-1 by HBECs in
response to IL-1
and TNF-
.
Am. J. Physiol. (Lung Cell. Mol. Physiol.)
273:
L866-L874
35. Sallenave, J. M., J. Shulmann, J. Crossley, M. Jordana, and J. Gauldie. 1994. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol. 11: 733-741 [Abstract].
36.
Atsuta, J.,
S. A. Sterbinsky,
J. Plitt,
L. M. Schwiebert,
B. S. Bochner, and
R. P. Schleimer.
1997.
Phenotyping and cytokine regulation of the BEAS-2B human bronchial epithelial cell: demonstration of inducible expression
of the adhesion molecules VCAM-1 and ICAM-1.
Am. J. Respir. Cell Mol.
Biol.
17:
571-582
37. Keppler, D., and B. F. Sloane. 1996. Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. Enzyme Protein 49: 94-105 [Medline].
38. Abrahamson, M.. 1994. Cystatins. Methods Enzymol. 244: 685-700 [Medline].
This article has been cited by other articles:
![]() |
M. Novinec, R. N. Grass, W. J. Stark, V. Turk, A. Baici, and B. Lenarcic Interaction between Human Cathepsins K, L, and S and Elastins: MECHANISM OF ELASTINOLYSIS AND INHIBITION BY MACROMOLECULAR INHIBITORS J. Biol. Chem., March 16, 2007; 282(11): 7893 - 7902. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. B. Acuff, M. Sinnamon, B. Fingleton, B. Boone, S. E. Levy, X. Chen, A. Pozzi, D. P. Carbone, D. R. Schwartz, K. Moin, et al. Analysis of Host- and Tumor-Derived Proteinases Using a Custom Dual Species Microarray Reveals a Protective Role for Stromal Matrix Metalloproteinase-12 in Non-Small Cell Lung Cancer Cancer Res., August 15, 2006; 66(16): 7968 - 7975. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Altiok, R. Yasumatsu, G. Bingol-Karakoc, R. J. Riese, M. T. Stahlman, W. Dwyer, R. A. Pierce, D. Bromme, E. Weber, and S. Cataltepe Imbalance between Cysteine Proteases and Inhibitors in a Baboon Model of Bronchopulmonary Dysplasia Am. J. Respir. Crit. Care Med., February 1, 2006; 173(3): 318 - 326. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sabo-Attwood, M. Ramos-Nino, J. Bond, K. J. Butnor, N. Heintz, A. D. Gruber, C. Steele, D. J. Taatjes, P. Vacek, and B. T. Mossman Gene Expression Profiles Reveal Increased mClca3 (Gob5) Expression and Mucin Production in a Murine Model of Asbestos-Induced Fibrogenesis Am. J. Pathol., November 1, 2005; 167(5): 1243 - 1256. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Buhling, C. Rocken, F. Brasch, R. Hartig, Y. Yasuda, P. Saftig, D. Bromme, and T. Welte Pivotal Role of Cathepsin K in Lung Fibrosis Am. J. Pathol., June 1, 2004; 164(6): 2203 - 2216. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Buhling, N. Waldburg, A. Reisenauer, A. Heimburg, H. Golpon, and T. Welte Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation Eur. Respir. J., April 1, 2004; 23(4): 620 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Aoshiba, N. Yokohori, and A. Nagai Alveolar Wall Apoptosis Causes Lung Destruction and Emphysematous Changes Am. J. Respir. Cell Mol. Biol., May 1, 2003; 28(5): 555 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.P. Dickinson CYSTEINE PEPTIDASES OF MAMMALS: THEIR BIOLOGICAL ROLES AND POTENTIAL EFFECTS IN THE ORAL CAVITY AND OTHER TISSUES IN HEALTH AND DISEASE Crit. Rev. Oral. Biol. Med., May 1, 2002; 13(3): 238 - 275. [Abstract] [Full Text] |
||||
![]() |
C. Rocken, B. Stix, D. Bromme, S. Ansorge, A. Roessner, and F. Buhling A Putative Role for Cathepsin K in Degradation of AA and AL Amyloidosis Am. J. Pathol., March 1, 2001; 158(3): 1029 - 1038. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Punturieri, S. Filippov, E. Allen, I. Caras, R. Murray, V. Reddy, and S. J. Weiss Regulation of Elastinolytic Cysteine Proteinase Activity in Normal and Cathepsin K-deficient Human Macrophages J. Exp. Med., September 11, 2000; 192(6): 789 - 800. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Tepel, D Bromme, V Herzog, and K Brix Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin J. Cell Sci., January 12, 2000; 113(24): 4487 - 4498. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |